Literature DB >> 2784754

Common variable hypogammaglobulinemia, recurrent Pneumocystis carinii pneumonia on intravenous gamma-globulin therapy, and natural killer deficiency.

V R Bonagura1, S Cunningham-Rundles, B L Edwards, N T Ilowite, J F Wedgwood, D J Valacer.   

Abstract

A toddler with common variable hypoimmunoglobulinemia (CVH), inflammatory bowel disease, and recurrent Pneumocystis carinii pneumonia (PCP) on intravenous gammaglobulin (IVIG) replacement was evaluated for a combined cellular immunodeficiency. He had a normal number of circulating T-cells, natural killer (NK) cells, T-cell subset percentages, and his peripheral blood mononuclear (PBM)-derived B-cell number was low. PBM mitogen blastogenesis and mixed lymphocyte reaction (MLR) were normal. MLR activated T-cells expressed class I and II MHC antigens, interleukin 2 (IL-2), and B-cell growth factor (IL-5)-related receptors. The patient's T-cells induced control B-cell maturation with pokeweed mitogen (PWM-PC), and did not suppress PWM-PC production by allogeneic PBM. Bone marrow (BM) CD19+ B-cell number varied between 10 and 44% of all PBM, and the BM B-cell-enriched fraction failed to differentiate to PWM-PC with autologous or allogeneic T-cell help. The NK activity assayed using K562 target cells was deficient, 9.2 x 7.7% (6.9-9.2%) pt, control 35.9 x 35.8% (16.3-67.2% +/- 12.8). In the presence of interferon-alpha, 800 U/ml, the patient's NK activity increased to 17.2 x 14.9% (12.6-17.2%), control 35.9 x 51.0% (36.5-72.3% +/- 12.0). The patient's cell-mediated lympholysis of HLA nonidentical, allogeneic stimulators was normal. Maintaining trough serum IgG levels above 500 mg/dl was required to suppress recurrent PCP. This functional NK deficiency may be relevant to the development of recurrent PCP in IVIG-treated CVH patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784754     DOI: 10.1016/0090-1229(89)90021-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  5 in total

1.  Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype.

Authors:  H B Gaspar; M Ferrando; I Caragol; M Hernandez; J M Bertran; X De Gracia; T Lester; C Kinnon; E Ashton; T Espanol
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

3.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

4.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

Review 5.  Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments.

Authors:  Aaron D Gingerich; Karen A Norris; Jarrod J Mousa
Journal:  Pathogens       Date:  2021-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.